SCHEMBL1891713

SCHEMBL1891713

O=C(C[C@@H]1Cc2cc(Cl)c3[nH]ncc3c2CN(CC(F)(F)F)C1=O)Nc1cnc2c(c1)CC1(C2)C(=O)Nc2ncccc21

nearest known ligand 0.53

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ CALCRL Q16602 20/20 0.53
▸ CYP3A4 P08684 1/20 0.49
▸ RAMP1 O60894 10/20 0.48
▸ RAMP3 O60896 1/20 0.44
▸ CALCR P30988 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1895077 0.87 CALCRL (0.51) CALCRL
SCHEMBL1891441 0.80 CALCRL (0.57) CALCRLCYP3A4RAMP1
SCHEMBL1896082 0.80 CALCRL (0.49) CALCRLCYP3A4RAMP1
SCHEMBL436142 0.77 CALCRL (0.63) CALCRLCYP3A4
SCHEMBL436141 0.77 CALCRL (0.63) CALCRLCYP3A4
SCHEMBL15701566 0.77 CALCRL (0.63) CALCRLCYP3A4
SCHEMBL1896085 0.75 CALCRL (0.46) CALCRLCYP3A4RAMP1
SCHEMBL15701573 0.75 CALCRL (0.64) CALCRLCYP3A4
SCHEMBL4048325 0.74 CALCRL (0.63) CALCRLCYP3A4
SCHEMBL436896 0.74 CALCRL (0.63) CALCRLCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2091533-B1 CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2012-11-28 — — EP disclosed
EP-2091533-B1 CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2012-11-28 — — EP disclosed
US-7951795-B2 Constrained spirocyclic compounds as CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-05-31 — — US disclosed
US-7951795-B2 Constrained spirocyclic compounds as CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-05-31 — — US disclosed
US-7951795-B2 Constrained spirocyclic compounds as CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-05-31 — — US disclosed
US-20100069359-A1 CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2010-03-18 — — US disclosed
US-20100069359-A1 CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2010-03-18 — — US disclosed
US-20100069359-A1 CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2010-03-18 — — US disclosed
WO-2008073251-A1 CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2008-06-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069359-A1 CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS CALCRL, BDKRB1, CALCR CALCRL 1/4885CYP3A4 3420/4885RAMP1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback